GB Patent

GB2630503A — Novel highly sustainable compositions for modulation of gene expression in human skin, and methods of production thereof

Assigned to Visolis Tech Inc · Expires 2024-11-27 · 1y expired

What this patent protects

Formulations containing biologically-produced, high-purity R-mevalonolactone are provided for modulating the expression of genes and metabolism related to epidermal turnover, hyaluronic acid synthesis, barrier function, anti-aging elasticity, extracellular matrix degradation, inf…

USPTO Abstract

Formulations containing biologically-produced, high-purity R-mevalonolactone are provided for modulating the expression of genes and metabolism related to epidermal turnover, hyaluronic acid synthesis, barrier function, anti-aging elasticity, extracellular matrix degradation, inflammation, stress, and pigmentation in human skin. The biologically-produced, high-purity R-mevalonolactone may be used as an ingredient in pharmaceutical, food, or cosmetic products and may be applied topically or ingested for modulation of gene expression and metabolism.

Drugs covered by this patent

Patent Metadata

Patent number
GB2630503A
Jurisdiction
GB
Classification
Expires
2024-11-27
Drug substance claim
No
Drug product claim
No
Assignee
Visolis Tech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.